Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Coinheritance of Triplicated Alpha-Globin Gene and Beta-Thalassemia Mutations in Adulthood: Ten Years of Referrals in Northern Greece.

Theodoridou S, Balassopoulou A, Boutou E, Delaki EE, Yfanti E, Vyzantiadis TA, Vetsiou E, Voskaridou E, Vlachaki E.

J Pediatr Hematol Oncol. 2020 Feb 6. doi: 10.1097/MPH.0000000000001730. [Epub ahead of print]

PMID:
32032239
2.

Detection of the sickle hemoglobin allele using a surface plasmon resonance based biosensor.

Breveglieri G, D'Aversa E, Cosenza LC, Boutou E, Balassopoulou A, Voskaridou E, Gambari R, Borgatti M.

Sens Actuators B Chem. 2019 Oct 1;296:126604. doi: 10.1016/j.snb.2019.05.081.

3.

Platelet function defects in patients with Gaucher disease on long term ERT- implications for evaluation at bleeding challenges.

Komninaka V, Repa K, Marinakis T, Pouliakis A, Koutsouri T, Tsokanas D, Flevary P, Voskaridou E, Politou M.

Blood Cells Mol Dis. 2020 Feb;80:102371. doi: 10.1016/j.bcmd.2019.102371. Epub 2019 Oct 18. No abstract available.

PMID:
31670186
4.

The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/βthal), correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hypertension.

Larissi K, Politou M, Margeli A, Poziopoulos C, Flevari P, Terpos E, Papassotiriou I, Voskaridou E.

Blood Cells Mol Dis. 2019 Jul;77:137-141. doi: 10.1016/j.bcmd.2019.04.011. Epub 2019 Apr 23.

PMID:
31071550
5.

Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density.

Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Dimopoulou M, Komninaka V, Repa K, Papatheodorou A, Terpos E.

Ann Hematol. 2019 Jul;98(7):1583-1592. doi: 10.1007/s00277-019-03695-x. Epub 2019 Apr 30.

PMID:
31041514
6.

Effect of heterozygous beta thalassemia on HbA1c levels in individuals without diabetes mellitus: A cross sectional study.

Tsilingiris D, Makrilakis K, Voskaridou E, Pagkrati S, Dalamaga M, Liatis S.

Clin Chim Acta. 2019 Jul;494:132-137. doi: 10.1016/j.cca.2019.03.1611. Epub 2019 Mar 13.

PMID:
30878538
7.

Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis.

Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Sonnleitner L, Papaefstathiou A, Dimopoulou M, Missbichler A, Kanellias N, Repa K, Papatheodorou A, Peppa M, Hawa G, Terpos E.

Hematology. 2019 Dec;24(1):318-324. doi: 10.1080/16078454.2019.1570617.

PMID:
30665323
8.

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.

Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, Caruso V, Pietrangelo A, Longo F, Tartaglione I, Borgna-Pignatti C, Zhang X, Laadem A, Sherman ML, Attie KM.

Blood. 2019 Mar 21;133(12):1279-1289. doi: 10.1182/blood-2018-10-879247. Epub 2019 Jan 7.

9.

Efficacy of the National Thalassaemia and Sickle Cell Disease Prevention Programme in Northern Greece: 15-Year Experience, Practice and Policy Gaps for Natives and Migrants.

Theodoridou S, Prapas N, Balassopoulou A, Boutou E, Vyzantiadis TA, Adamidou D, Delaki EE, Yfanti E, Economou M, Teli Α, Karakasidou O, Skatharoudi E, Theodoridis T, Voskaridou E.

Hemoglobin. 2018 Jul;42(4):257-263. doi: 10.1080/03630269.2018.1528986. Epub 2018 Dec 3.

PMID:
30501529
10.

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.

Voskaridou E, Ntanasis-Stathopoulos I, Papaefstathiou A, Christoulas D, Dimopoulou M, Repa K, Papatheodorou A, Peppa M, Terpos E.

Blood Adv. 2018 Nov 13;2(21):2837-2847. doi: 10.1182/bloodadvances.2018023085.

11.

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.

Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Galactéros F, Taher AT, Arlet JB, Ribeil JA, Garbowski M, Graziadei G, Brouzes C, Semeraro M, Laadem A, Miteva D, Zou J, Sung V, Zinger T, Attie KM, Hermine O.

Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18.

12.

A Novel BaEVRless-Pseudotyped γ-Globin Lentiviral Vector Drives High and Stable Fetal Hemoglobin Expression and Improves Thalassemic Erythropoiesis In Vitro.

Drakopoulou E, Georgomanoli M, Lederer CW, Kleanthous M, Costa C, Bernadin O, Cosset FL, Voskaridou E, Verhoeyen E, Papanikolaou E, Anagnou NP.

Hum Gene Ther. 2019 May;30(5):601-617. doi: 10.1089/hum.2018.022. Epub 2019 Mar 15.

PMID:
30324804
13.

National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality.

Voskaridou E, Kattamis A, Fragodimitri C, Kourakli A, Chalkia P, Diamantidis M, Vlachaki E, Drosou M, Lafioniatis S, Maragkos K, Petropoulou F, Eftihiadis E, Economou M, Klironomos E, Koutsouka F, Nestora K, Tzoumari I, Papageorgiou O, Basileiadi A, Lafiatis I, Dimitriadou E, Kalpaka A, Kalkana C, Xanthopoulidis G, Adamopoulos I, Kaiafas P, Mpitzioni A, Goula A, Kontonis I, Alepi C, Anastasiadis A, Papadopoulou M, Maili P, Dionisopoulou D, Tsirka A, Makis A, Kostaridou S, Politou M, Papassotiriou I; Greek Haemoglobinopathies Study Group.

Ann Hematol. 2019 Jan;98(1):55-66. doi: 10.1007/s00277-018-3493-4. Epub 2018 Sep 8.

PMID:
30196444
14.

2017 Clinical trials update in new treatments of β-thalassemia.

Makis A, Hatzimichael E, Papassotiriou I, Voskaridou E.

Am J Hematol. 2016 Nov;91(11):1135-1145. doi: 10.1002/ajh.24530. Review.

15.

Development of a High-Resolution Melting Approach for Scanning Beta Globin Gene Point Mutations in the Greek and Other Mediterranean Populations.

Chassanidis C, Boutou E, Voskaridou E, Balassopoulou A.

PLoS One. 2016 Jun 28;11(6):e0157393. doi: 10.1371/journal.pone.0157393. eCollection 2016.

16.

Evaluation of bone involvement in patients with Gaucher disease: a semi-quantitative magnetic resonance imaging method (using ROI estimation of bone lesion) as an alternative method to semi-quantitative methods used so far.

Komninaka V, Kolomodi D, Christoulas D, Marinakis T, Papatheodorou A, Repa K, Voskaridou E, Revenas K, Terpos E.

Eur J Haematol. 2015 Oct;95(4):342-51. doi: 10.1111/ejh.12504. Epub 2015 Mar 23.

PMID:
25645321
17.

The Economic Burden of Treating Thalassemia In Greece.

Geitona M, Karagianni V, Kattamis A, Voskaridou E, Drosou M, Vini D, Kalogeropoulou M.

Value Health. 2014 Nov;17(7):A526. doi: 10.1016/j.jval.2014.08.1661. Epub 2014 Oct 26. No abstract available.

18.

Pregnancy in beta-thalassemia intermedia: 20-year experience of a Greek thalassemia center.

Voskaridou E, Balassopoulou A, Boutou E, Komninaka V, Christoulas D, Dimopoulou M, Delaki EE, Loukopoulos D, Terpos E.

Eur J Haematol. 2014 Dec;93(6):492-9. doi: 10.1111/ejh.12387. Epub 2014 Jun 26.

PMID:
24889414
19.

Co-Existence of Hereditary Pyrimidine 5'-Nucleotidase Deficiency and Heterozygous α-Thalassemia: A Case Presentation.

Agapidou A, Theodoridou S, Tegos K, Mandala E, Leukou E, Karakasidou O, Aletra B, Sevastidou A, Alemayehou M, Voskaridou E.

Turk J Haematol. 2012 Dec;29(4):434-5. doi: 10.5505/tjh.2012.48642. Epub 2012 Dec 5. No abstract available.

20.

Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.

Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.

Transfusion. 2014 Mar;54(3):646-9. doi: 10.1111/trf.12335. Epub 2013 Jul 9.

PMID:
23834310
21.

Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit.

Vafiadis I, Trilianos P, Vlachogiannakos J, Karagiorga M, Hatziliami A, Voskaridou E, Ladas SD.

Ann Hepatol. 2013 Jul-Aug;12(4):532-8.

22.

Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection.

Kountouras D, Tsagarakis NJ, Fatourou E, Dalagiorgos E, Chrysanthos N, Berdoussi H, Vgontza N, Karagiorga M, Lagiandreou A, Kaligeros K, Voskaridou E, Roussou P, Diamanti-Kandarakis E, Koskinas J.

Liver Int. 2013 Mar;33(3):420-7. doi: 10.1111/liv.12095.

PMID:
23402611
23.

High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.

Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E.

Horm Metab Res. 2012 Nov;44(12):909-13. doi: 10.1055/s-0032-1312618. Epub 2012 May 11.

PMID:
22581647
24.

Sickle-cell disease and the heart: review of the current literature.

Voskaridou E, Christoulas D, Terpos E.

Br J Haematol. 2012 Jun;157(6):664-73. doi: 10.1111/j.1365-2141.2012.09143.x. Epub 2012 Apr 25. Review.

PMID:
22530942
25.

A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births.

Voskaridou E, Ladis V, Kattamis A, Hassapopoulou E, Economou M, Kourakli A, Maragkos K, Kontogianni K, Lafioniatis S, Vrettou E, Koutsouka F, Papadakis A, Mihos A, Eftihiadis E, Farmaki K, Papageorgiou O, Tapaki G, Maili P, Theohari M, Drosou M, Kartasis Z, Aggelaki M, Basileiadi A, Adamopoulos I, Lafiatis I, Galanopoulos A, Xanthopoulidis G, Dimitriadou E, Mprimi A, Stamatopoulou M, Haile ED, Tsironi M, Anastasiadis A, Kalmanti M, Papadopoulou M, Panori E, Dimoxenou P, Tsirka A, Georgakopoulos D, Drandrakis P, Dionisopoulou D, Ntalamaga A, Davros I, Karagiorga M; Greek Haemoglobinopathies Study Group.

Ann Hematol. 2012 Sep;91(9):1451-8. Epub 2012 Apr 19.

PMID:
22526366
26.

Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.

Voskaridou E, Christoulas D, Terpos E.

Br J Haematol. 2011 Sep;154(5):654-6. doi: 10.1111/j.1365-2141.2011.08626.x. Epub 2011 May 25. No abstract available.

PMID:
21615376
27.

Treatment options for thalassemia patients with osteoporosis.

Terpos E, Voskaridou E.

Ann N Y Acad Sci. 2010 Aug;1202:237-43. doi: 10.1111/j.1749-6632.2010.05542.x.

PMID:
20712799
28.

Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.

Voskaridou E, Plata E, Douskou M, Sioni A, Mpoutou E, Christoulas D, Dimopoulou M, Terpos E.

Ann Hematol. 2011 Jan;90(1):11-5. doi: 10.1007/s00277-010-1029-7. Epub 2010 Jul 27.

PMID:
20661572
29.

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Blood. 2010 Mar 25;115(12):2354-63. doi: 10.1182/blood-2009-05-221333. Epub 2009 Nov 10.

PMID:
19903897
30.

Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.

Voskaridou E, Plata E, Douskou M, Papadakis M, Delaki EE, Christoulas D, Terpos E.

Br J Haematol. 2010 Jan;148(2):332-4. doi: 10.1111/j.1365-2141.2009.07930.x. Epub 2009 Oct 26. No abstract available.

PMID:
19863539
31.

An electronic infrastructure for research and treatment of the thalassemias and other hemoglobinopathies: the Euro-mediterranean ITHANET project.

Lederer CW, Basak AN, Aydinok Y, Christou S, El-Beshlawy A, Eleftheriou A, Fattoum S, Felice AE, Fibach E, Galanello R, Gambari R, Gavrila L, Giordano PC, Grosveld F, Hassapopoulou H, Hladka E, Kanavakis E, Locatelli F, Old J, Patrinos GP, Romeo G, Taher A, Traeger-Synodinos J, Vassiliou P, Villegas A, Voskaridou E, Wajcman H, Zafeiropoulos A, Kleanthous M.

Hemoglobin. 2009;33(3):163-76. doi: 10.1080/03630260903089177.

PMID:
19657830
32.

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, Kastritis E, Papatheodorou A, Terpos E.

Haematologica. 2009 May;94(5):725-8. doi: 10.3324/haema-tol.2008.000893. Erratum in: Haematologica. 2009 Aug;94(8):1182.

33.

Interactions between osteoclasts, osteoblasts and immune cells: implications for the pathogenesis of bone loss in thalassemia.

Terpos E, Voskaridou E.

Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:94-106. Review.

PMID:
19337162
34.

Pathogenesis and management of osteoporosis in thalassemia.

Voskaridou E, Terpos E.

Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:86-93. Review.

PMID:
19337161
35.

Carrier screening and prenatal diagnosis of hemoglobinopathies. A study of indigenous and immigrant couples in northern Greece, over the last 5 years.

Theodoridou S, Alemayehou M, Prappas N, Karakasidou O, Aletra V, Plata E, Tsaftaridis P, Karababa P, Boussiou M, Sinopoulou K, Hatzi A, Voskaridou E, Loutradi A, Manitsa A.

Hemoglobin. 2008;32(5):434-9. doi: 10.1080/03630260802341745.

PMID:
18932067
36.

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.

Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E.

Haematologica. 2008 Oct;93(10):1588-90. doi: 10.3324/haematol.12849. Epub 2008 Aug 12. No abstract available.

37.

Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.

Voskaridou E, Christoulas D, Antoniadou L, Terpos E.

Acta Haematol. 2008;119(1):40-4. doi: 10.1159/000114869. Epub 2008 Feb 5. No abstract available.

PMID:
18253025
38.

Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations.

Voskaridou E, Tsetsos G, Tsoutsias A, Spyropoulou E, Christoulas D, Terpos E.

Haematologica. 2007 Jun;92(6):738-43.

39.

Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.

Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E.

Haematologica. 2006 Sep;91(9):1193-202.

40.

Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis.

Voskaridou E, Stoupa E, Antoniadou L, Premetis E, Konstantopoulos K, Papassotiriou I, Terpos E.

Haematologica. 2006 Jun;91(6):813-6. Epub 2006 May 16.

41.

Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia.

Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, Simirloglou D, Loukopoulos D, Papassotiriou I.

Kidney Int. 2006 Jun;69(11):2037-42.

42.
43.

Deferiprone as an oral iron chelator in sickle cell disease.

Voskaridou E, Douskou M, Terpos E, Stamoulakatou A, Meletis J, Ourailidis A, Papassotiriou I, Loukopoulos D.

Ann Hematol. 2005 Jul;84(7):434-40. Epub 2005 Apr 5.

PMID:
15809885
44.
45.

New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia.

Voskaridou E, Terpos E.

Br J Haematol. 2004 Oct;127(2):127-39. Review.

PMID:
15461618
46.

Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.

Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A, Loutradi A, Loukopoulos D.

Br J Haematol. 2004 Sep;126(5):736-42.

PMID:
15327528
47.

Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.

Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D.

Br J Haematol. 2003 Nov;123(4):730-7.

PMID:
14616979
48.

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.

Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C, Vaiopoulos G, Palermos J, Yataganas X, Goldman JM, Rahemtulla A.

Eur J Haematol. 2003 Jan;70(1):34-42.

PMID:
12631257
49.

Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.

Steinberg MH, Voskaridou E, Kutlar A, Loukopoulos D, Koshy M, Ballas SK, Castro O, Barton F.

Am J Hematol. 2003 Feb;72(2):121-6.

50.

Inverse correlation of plasma leptin and soluble transferrin receptor levels in beta-thalassemia patients.

Dedoussis GV, Kyrtsonis MC, Andrikopoulos NE, Voskaridou E, Loutradis A.

Ann Hematol. 2002 Sep;81(9):543-7. Epub 2002 Sep 6.

PMID:
12373360

Supplemental Content

Loading ...
Support Center